UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Annals of oncology, 2012-07, Vol.23 (7), p.1680-1687

2012

Volltextzugriff (PDF)

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hematological oncology, 2023-06, Vol.41 (S2), p.587-589

2023

Volltextzugriff (PDF)

Assessing the thermoelectric properties of single InSb nanowires: the role of thermal contact resistance

Semiconductor science and technology, 2016-06, Vol.31 (6), p.64001

2016

Volltextzugriff (PDF)

Nisin production conditions optimization and its effect on Bacillus cereus and Listeria monocytogenes

International food research journal, 2017-04, Vol.24 (2), p.900

2017

Volltextzugriff (PDF)

Local modification of GaAs nanowires induced by laser heating

Nanotechnology, 2011-08, Vol.22 (32), p.325701-1-5

2011

Volltextzugriff (PDF)

P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

HemaSphere, 2022-06, Vol.6 (Suppl), p.1041-1042

2022

Volltextzugriff (PDF)

PP-149 GLUCOSE LEVEL IN PATIENTS WITHIN RECENT ACUTE CORONARY SYNDROME WHO UNDERGO CORONARY ANGIOGRAPHY

International journal of cardiology, 2013-03, Vol.163 (3), p.S139-S139

2013

Volltextzugriff (PDF)

PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii105-ii105

2016

Volltextzugriff (PDF)

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

Leukemia, 2003-11, Vol.17 (11), p.2101-2106

2003

Volltextzugriff (PDF)

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3766-3770

2001

Volltextzugriff (PDF)

The spectrum of β-thalassemia mutations in Gaza Strip, Palestine

Blood cells, molecules, & diseases, 2013-04, Vol.50 (4), p.247-251

2013

Volltextzugriff (PDF)

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma

Annals of oncology, 2002-03, Vol.13 (3), p.450-459

2002

Volltextzugriff (PDF)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Hematological oncology, 2023-06, Vol.41 Suppl 2, p.587

2023

Volltextzugriff (PDF)

A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

Annals of oncology, 2015-03, Vol.26, p.ii16

2015

Volltextzugriff (PDF)

P1.10A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

Annals of oncology, 2015-03, Vol.26 (suppl_2), p.ii18-ii18

2015

Volltextzugriff (PDF)

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

European journal of cancer supplements, 2008, Vol.6 (12), p.124-124

2008

Volltextzugriff (PDF)

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

European journal of cancer supplements, 2008, Vol.6 (12), p.67-67

2008

Volltextzugriff (PDF)

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.120-120

2008

Volltextzugriff (PDF)

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

Annals of oncology, 2016-10, Vol.27, p.vi116-vi116

2016

Volltextzugriff (PDF)

Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5094-5094

2007

Volltextzugriff (PDF)

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10017-10017

2010

Volltextzugriff (PDF)

Iseganan HCl: a novel antimicrobial agent

Expert opinion on investigational drugs, 2002-08, Vol.11 (8), p.1161-1170

2002

Volltextzugriff (PDF)

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.4549-4549

2007

Volltextzugriff (PDF)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4535-4535

2006

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(50)
Humans
(37)
Male
(24)
Female
(23)
Middle Aged
(18)
Aged
(17)
Adult
(14)
Patients
(14)
Technology
(13)
Physical Sciences
(11)
Aged, 80 And Over
(10)
Cardiac & Cardiovascular Systems
(10)
Cardiovascular System & Cardiology
(10)
Science & Technology - Other Topics
(10)
Animals
(9)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Mortality
(9)
Surgery
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Assessing the thermoelectric properties of single InSb nanowires: the role of thermal contact resistance

Nisin production conditions optimization and its effect on Bacillus cereus and Listeria monocytogenes

Local modification of GaAs nanowires induced by laser heating

P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA

PP-149 GLUCOSE LEVEL IN PATIENTS WITHIN RECENT ACUTE CORONARY SYNDROME WHO UNDERGO CORONARY ANGIOGRAPHY

PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

The spectrum of β-thalassemia mutations in Gaza Strip, Palestine

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

P1.10A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study

PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)

Final results from phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3

Iseganan HCl: a novel antimicrobial agent

Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)

Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Suchergebnisse filtern